ALBERTDAVD2021-10-012021-12-31in-bse-fin:OneOperatingExpenses01Member ALBERTDAVD2021-10-012021-12-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares ALBERTDAVD 2021-04-01 2022-03-31 2022-02-04 INR Lakhs Third quarter Single segment Pharmaceuticals 2021-10-01 2021-12-31 Unaudited Standalone 716989000.00 60280000.00 777269000.00 127860000.00 147319000.00 -16234000.00 203731000.00 1043000.00 23131000.00 181698000.00 668548000.00 108721000.00 0.00 108721000.00 21781000.00 7282000.00 29063000.00 0.00 79658000.00 0.00 0.00 0.00 0.00 79658000.00 -838000.00 78820000.00 0.00 0.00 57072000.00 10 13.96 13.96 0.00 0.00 13.96 13.96 1) The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 14th February, 2022 apart from being subjected to Limited Review for the quarter and nine months ended 31st December, 2021 by the Statutory Auditors, as required under Regulation 33 of SEBI (LO&DR) Regulations, 2015. 2) The Statutory Auditors of the Company have issued an unmodified review report on the Unaudited Financial Results for the quarter and nine months ended 31st December, 2021. 3) As per current indication, rage of COVID-19 has reduced though the quarter under review was in turmoil with added proliferation albeit reduced intensity of the attack of the pandemic. Present indicators of future economic conditions more or less affirm recoverability/retention of the carrying amounts of the assets with low possibility of material change subsequently. Vaccination drive covering majority of populance in domestic and international context further promises decline in vicissitude of the pandemic in near future. 4) The Company is engaged in the manufacturing of pharmaceuticals and has only one reportable segment in accordance with Ind AS-108 Operating Segments . 5) Figures for the previous periods are regrouped to conform to the figures of the current period as and when required in limited context of format of financial results and disclosures thereon specified by SEBI. Single segment 2021-04-01 2021-12-31 Unaudited Standalone 2391386000.00 165268000.00 2556654000.00 387249000.00 438716000.00 52472000.00 647879000.00 3624000.00 64164000.00 557265000.00 2151369000.00 405285000.00 0.00 405285000.00 93614000.00 835000.00 94449000.00 0.00 310836000.00 0.00 0.00 0.00 0.00 310836000.00 4607000.00 315443000.00 0.00 0.00 57072000.00 10 54.46 54.46 0.00 0.00 54.46 54.46 Other expenses 181698000.00 Other expenses 557265000.00